Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 272

Sort by

Sort Order Select

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, MD PhD, Roberto E. Cacchione, MD, Wojciech Jurczak, MD PhD, Cheolwon Suh, Lorenz Truemper, MD, Christian W Scholz

Blood (2019) 134 (Supplement_1): 5263.

https://doi.org/10.1182/blood-2019-124192

Published: 2019

Journal Articles

Implementation of a Cardio Oncology Protocol in Uruguay

Pía Oldan, MD, Andreina Gomez, MD, Gabriel Parma, MD, Cecilia Guillermo, MD, Lilián Díaz, MD, Matilde Boada, MD MSc

Blood (2019) 134 (Supplement_1): 5888.

https://doi.org/10.1182/blood-2019-127068

Published: 2019

Journal Articles

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Harinder Gill, FRCP, FRCPath, Rita Yim, PhD, Cyrus R Kumana, FRCP, Yok-Lam Kwong, MD

Blood (2019) 134 (Supplement_1): 3853.

https://doi.org/10.1182/blood-2019-125185

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 4081.

https://doi.org/10.1182/blood-2019-123449

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Fahrettin Covut, MD, Gayathri Ravi, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 3174.

https://doi.org/10.1182/blood-2019-126059

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, José Luis Díez-Martín, MD PhD, Benedetto Bruno, MD, Simona Sica, MD, Yener Koc, MD, Zafer Gulbas, MD, Christoph Schmid, MD, Didier Blaise, MD PhD, Angelo Michele Carella, Giuseppe Visani, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4584.

https://doi.org/10.1182/blood-2019-122279

Published: 2019

Journal Articles

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Yuki Aoki, Akira Hayakawa, MD PhD, Kazutoshi Koike, MD PhD, Hisamichi Tauchi, MD PhD, Eiichi Ishii, MD PhD, Katsuyoshi Koh, MD, Takako Miyamura, MD PhD, Yasushi Ishida, MD PhD, Akiko Kada, MPH, Akiko M Saito, MD PhD, Atsushi Manabe, MD PhD, Keizo Horibe, MD PhD, Shuki Mizutani, MD PhD, Miho Maeda, MD, Daisuke Tomizawa, MD PhD

Blood (2019) 134 (Supplement_1): 4559.

https://doi.org/10.1182/blood-2019-123881

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

Outcome Among Adolescents and Young Adults with Acute Myeloid Leukemia at Pediatric Versus Adult Centers: A Population-Based Study Using the IMPACT Cohort

Sumit Gupta, MD, Nancy Baxter, MD PhD, Jason Pole, PhD, Cindy Lau, MPH, Rinku Sutradhar, PhD, Chenthila Nagamuthu, MPH, Paul Nathan, MD

Blood (2019) 134 (Supplement_1): 4749.

https://doi.org/10.1182/blood-2019-130145

Published: 2019

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Nishi Shah, MBBS, MPH, Mohammad Kazemi, Stephen Zachary Peeke, MD, Lizamarie Bachier-rodriguez, R.Alejandro Sica, MD, Noah Kornblum, MD, Ira Braunschweig, MD, Aditi Shastri, MD, Amit Verma, MBBS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 426.

https://doi.org/10.1182/blood-2019-123168

Published: 2019

Journal Articles

Primary and Secondary Hematological Neoplasms - Are They Related?

Claudia Haferlach, MD, Constance Baer, PhD, Stephan Hutter, PhD, Anna Stengel, PhD, Niroshan Nadarajah, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 1702.

https://doi.org/10.1182/blood-2019-126585

Published: 2019

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2019) 134 (Supplement_1): 330.

https://doi.org/10.1182/blood-2019-127568

Published: 2019

Journal Articles

Impact of Competing Treatment Scenarios on Lifetime Disease Burden and Quality Adjusted Life Expectancy (QALE) Among Survivors of High-Risk Childhood Hodgkin Lymphoma (HR-HL): A Modeling Study Based on the St. Jude Lifetime (SJLIFE) Cohort

Nickhill Bhakta, Kalatu Davies, PhD, Jesse Turner, PhD, Yichen Chen, PhD, Jaime Flerlage, MD MS, I-Chan Huang, PhD, Melissa M. Hudson, MD, John T. Lucas, Jr., MD MS, Monika Metzger, MD, Leslie L. Robison, PhD, F. Lennie Wong, PhD

Blood (2019) 134 (Supplement_1): 267.

https://doi.org/10.1182/blood-2019-124907

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Implementation of a Cardio Oncology Protocol in Uruguay

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Outcome Among Adolescents and Young Adults with Acute Myeloid Leukemia at Pediatric Versus Adult Centers: A Population-Based Study Using the IMPACT Cohort

ATM Germline Variant Increases the Risk of MPN Progression

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Primary and Secondary Hematological Neoplasms - Are They Related?

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Impact of Competing Treatment Scenarios on Lifetime Disease Burden and Quality Adjusted Life Expectancy (QALE) Among Survivors of High-Risk Childhood Hodgkin Lymphoma (HR-HL): A Modeling Study Based on the St. Jude Lifetime (SJLIFE) Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only